This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gelfand, E. V. Articles by Cannon, C. P. Search for Related Content PubMed PubMed Citation Articles by Gelfand, E. V. Articles by Cannon, C. P.

Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors

Eli V. Gelfand, MD^_* and Christopher P. Cannon, MD^,_*

^_* Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

View larger version (25K): [in a new window]   Figure 1 Change in body weight among subjects in the Rimonabant in Obesity (RIO)-Lipids study. Reprinted, with permission, from Despres et al. (62).

View larger version (8K): [in a new window]   Figure 2 Percentage of subjects achieving 10% weight loss at one year with rimonabant (solid bars) 20 mg/day versus placebo (open bars) in the first two Rimonabant in Obesity (RIO) trials among those completing the study.